Remix to leverage REMaster™ platform to discover novel drugs for a diverse range of target classes
Remix will receive $30 million upfront and is eligible to receive up to $12 million in.
Remix Therapeutics announced on Wednesday that it has entered into a collaboration and licensing agreement with Roche for the development of small molecule RNA therapeutics.In a press release, Roche.
/PRNewswire/ Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying.
/PRNewswire/ Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying.